Grant Validation NIH grants totaling 9.5 million, plus a 2.9 million grant awarded in Sep 2025, signal strong validation and active funding momentum for Scanogen's culture-free bloodstream infection and point-of-care programs. This funding backdrop creates compelling entry points for pilots, regulatory support packages, and co-development partnerships with hospital systems as you move toward commercialization.

POC and BSI The focus on point-of-care diagnosis and bloodstream infection detection with a simple to use sample-to-answer platform opens opportunities to sell to emergency departments, ICUs, and hospital clinical labs seeking faster pathogen results and improved patient care. Target multi-site hospital networks for pilots and demonstrate workflow gains compatible with existing LIS and EMR integrations.

SMOLT Advantage Single Molecule Tethering offers ultra-sensitive detection that can outperform culture-based methods, a strong differentiator for buyers. Leverage this to pursue co-development with instrument vendors or distributors and pursue OEM or reagent licensing deals to scale field adoption while supporting training and support services.

Niche Differentiation In a market dominated by large players, position Scanogen as a specialist for culture-free fungal bloodstream infections and rapid molecular readouts. Explore partnerships with mid-sized hospital groups and reference labs, plus licensing or distribution agreements to expand geography and speed onboarding of customers not served by larger incumbents.

Pilot Readiness With a lean team and revenue in the lower-mid range, Scanogen is well placed to run targeted pilots and early-access programs. Propose joint funded pilots with health systems, academic centers, and NIH grant collaborators, and align sales efforts with CROs and contract manufacturers to accelerate scale-up and commercialization.